Gracell Biotechnologies Inc is a global clinical-stage biopharmaceutical company. The company specializes in developing cell therapies for the treatment of cancer and autoimmune diseases, utilizing allogeneic and autologous platforms to produce CAR-T cell therapies. Gracell has developed FasTCAR and TruUCAR technology platforms and a SMART CARTTM technology module. They have also developed a 2nd generation enhanced CAR-T molecule for treating solid tumors and have been granted FDA Orphan Drug Designation for their BCMA/CD19 dual-targeting CAR-T cell therapy candidate GC012F for the treatment of multiple myeloma. Gracell has also dosed the first patients in a First-in-Human clinical trial evaluating GC012F for the treatment of B-Cell Non-Hodgkin's Lymphoma.
Headquarters
Building 12, Block B, Phase Ii, Biobay Industrial Park, 218 Sangtian Street, Suzhou Industrial Park
Suzhou; Jiangsu;
Postal Code: 215123
Contact Details: Purchase the Gracell Biotechnologies Inc. report to view the information.
Website: http://www.gracellbio.com/
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service